BMD 1111

Drug Profile

BMD 1111

Alternative Names: BMD-1111

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arkansas System
  • Developer BiologicsMD
  • Class Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Osteoporosis

Most Recent Events

  • 12 Jun 2012 Preclinical trials in Osteoporosis in USA (unspecified route)
  • 09 Feb 2011 BiologicsMD's osteoporosis therapy is available for licensing as of 09 Feb 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top